Sectors
LBRX
LB Pharmaceuticals Inc
47.26
2 x 32.42
2 x 57.43
bid
ask
-
0.47
0.98%
2 @ 07:30 PM
47.26 +0.00 (0.00%)
| Ytd | 112.31% | |
| 1y | 173.18% |
46.38
day range
47.50
13.36
52 week range
50.16
| Open | 47.47 | Prev Close | 47.73 | Low | 46.38 | High | 47.50 | Mkt Cap | 1.52B |
| Vol | 386.95K | Avg Vol | 325.77K | EPS | -5.10 | P/E | N/A | Forward P/E | -9.38 |
| Beta | N/A | Short Ratio | 13.65 | Inst. Own | 101.37% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 38.74 | 200-d Avg | 27.88 | 1yr Est | 53.38 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-05 | 2026-09 | -1.61 | N/A | N/A | N/A |
| 2026-08-11 | 2026-06 | -0.8 | -1.71 | -0.91 | -112.78% |
| 2026-05-12 | 2026-03 | -0.75 | -0.67 | 0.08 | 10.67% |
| 2026-03-26 | 2025-12 | -0.45 | -0.45 | N/A | N/A |
| 2025-11-06 | 2025-09 | -0.57 | -0.61 | -0.04 | -7.02% |
| 2025-09-08 | 2025-06 | 0 | -1.44 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-24 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-08-12 | BMO Capital | Upgrade | Outperform | Outperform |
| 2026-08-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-21 | BMO Capital | Upgrade | Outperform | |
| 2026-07-07 | Wolfe Research | Upgrade | Outperform | |
| 2026-04-27 | HC Wainwright & Co. | Upgrade | Buy |
Profile
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-09-11 | DEEP TRACK BIOTECHNOLOGY MASTER FUND LTD | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2025-09-11 | NUSSBAUM RAN | Director | 0.00 | Conversion of Exercise of derivative security |
| 2025-09-11 | PONTIFAX MANAGEMENT 4 G.P. 2015, LTD. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2025-09-11 | VIDA VENTURES GP III, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Deep Track Capital, Lp | 3.35M | 158.45M | 10.39% |
| 2026-06-29 | Blackrock Inc. | 2.73M | 129.22M | 8.48% |
| 2026-06-29 | RA Capital Management, L.P. | 2.21M | 104.38M | 6.85% |
| 2026-06-29 | Trails Edge Capital Partners, LP | 1.52M | 71.98M | 4.72% |
| 2026-06-29 | Commodore Capital Lp | 1.50M | 70.89M | 4.65% |
| 2026-06-29 | JPMORGAN CHASE & CO | 1.50M | 70.76M | 4.64% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 729.32K | 34.47M | 2.26% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 599.10K | 28.31M | 1.86% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 581.75K | 27.49M | 1.80% |
| 2026-05-30 | BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 567.63K | 26.83M | 1.76% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 274.12K | 12.96M | 0.85% |
| 2026-03-30 | JPMorgan Trust I-JPMorgan Small Cap Blend Fund | 235.45K | 11.13M | 0.73% |